Zhitong Finance App News, Sinopharm Hyundai (600420.SH) issued an announcement. Recently, Sinopharm Group Rongsheng Pharmaceutical Co., Ltd. (Sinopharm Rongsheng for short), a wholly-owned subsidiary of the company, received the “Drug Registration Certificate” for bumetanib injection (2ml: 1mg) approved and issued by the China Drug Administration.

Bumetanib injections are mainly used for: (1) edematous diseases, including congestive heart failure, liver cirrhosis, kidney disease, treatment of acute pulmonary edema and acute brain edema with other drugs; (2) hypertension; (3) prevention of acute renal failure; (4) hyperkalemia and hypercalcemia; (5) dilute hyponatremia; (6) excessive secretion of antidiuretic hormone; (7) acute drug toxicosis, etc.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.